CellSeed Inc. Second Quarter (Mid-Year) Financial Summary

Overview of performance

CellSeed recorded net sales of 20,820 thousand yen in the interim period, down year over year. Operating loss was 570,958 thousand yen, ordinary loss 576,215 thousand yen, and interim net loss 610,611 thousand yen, continuing to post deficits. Both the Regenerative Medicine Support Business and the Cell Sheet Regenerative Medicine Business are pursuing sales growth, with particular emphasis on the Phase 3 trial for allogeneic chondrocyte sheet (CLS2901C); timing for approval and monetization remains uncertain. Cash on hand is stabilized by funds raised through exercise of new stock acquisition rights.

Outlook and impact for investors

Full-year earnings guidance remains unchanged from the time of release. Accelerating commercialization of the first product and pursuing business collaborations are key to realizing revenue opportunities; the formation of partnerships and progress of clinical trials are critical. While the financial position has been strengthened by capital proceeds from the exercise of stock acquisition rights, uncertainty remains until approval and monetization, so investors should monitor R&D progress and liquidity stability.